Solid Biosciences prices $200M underwritten offering; extends cash runway into first half 2027

Solid Biosciences Inc.

Priced $200M underwritten offering expected to close Feb 19, 2025; net proceeds to fund R&D for SGT-003 and other candidates.
Company estimates cash runway into first half of 2027, but notes offering alone may not fully fund development of all candidates.
Remaining proceeds for general corporate purposes; existing cash and securities combined for operating plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.